BOARD OF DIRECTORS

Eric Dube, Ph.D., is the president and chief executive officer of Travere Therapeutics and serves as a member of the company’s board of directors. He is a results-driven leader who is committed to patients and integrating their perspective into all aspects of the company’s operations. At Travere Therapeutics, Dr. Dube oversees a global team dedicated to identifying, developing and delivering life-changing therapies to people living with rare disease, including the company’s promising pipeline of innovative product candidates with first-in-class potential. With leadership experience across the United States, Europe and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical and business development functions.

Prior to joining Travere Therapeutics, Dr. Dube was president and head of North America at ViiV Healthcare. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain and alliance management. During Dr. Dube’s tenure at GSK, he also led the US Oncology and Global Respiratory businesses. He currently serves on the executive committee of the board of directors for the Biotechnology Innovation Organization (BIO), and the board of directors for Reneo Pharmaceuticals.

Dr. Dube was named a 2022 Ernst & Young Entrepreneur of the Year Pacific Southwest winner. Dr. Dube has been recognized by PharmaVOICE magazine as one of the “100 Most Inspiring People” in the life sciences industry, the Financial Times as one of the “OUTstanding 100 LGBT+ Executives, and Pharmaceutical Executive as one of the “Emerging Pharma Leaders”. Earlier in his career, Fortune magazine named him a “40 Under 40: Ones to Watch”.

Dr. Dube graduated from Santa Clara University with a B.S. in biopsychology and earned an M.A. and Ph.D. in psychology from Cornell University.